Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
52°
Site search
Search
Menu
Subscribe
Home
News
Local News
Sports
Obituaries
Photos
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Explore the Sheyenne
Best of 2023
Archives
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Relief Therapeutics Hldg Ag
(OP:
RLFTF
)
1.440
+0.065 (+4.73%)
Streaming Delayed Price
Updated: 9:55 AM EDT, May 17, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Relief Therapeutics Hldg Ag
< Previous
1
2
3
4
5
6
Next >
Relief Files Trademark Application for RLF-100 With the U.S. Patent and Trademark Office
February 08, 2022
No Notice of Opposition or Extension Request has Been Received in Relation to the Application; Certificate of Registration Expected by Late April GENEVA, SWITZERLAND / ACCESSWIRE /February 8, 2022 /...
From
Relief Therapeutics Holdings AG
Via
AccessWire
Topics
Intellectual Property
Exposures
Intellectual Property
Relief Therapeutics Expands Its Board of Directors with the Appointment of Michelle Lock
February 02, 2022
Industry Executive Brings Nearly 30 Years of Biopharmaceutical Sales and Commercial Expertise GENEVA, SWITZERLAND / ACCESSWIRE / February 2, 2022 / RELIEF THERAPEUTICS Holding SA...
From
Relief Therapeutics Holdings AG
Via
AccessWire
Relief Announces That Collaboration Partner, Acer Therapeutics, was Issued U.S. Patent 11,202,767 Covering ACER-001 Methods of Use for Treatment of Urea Cycle Disorders and Maple Syrup Urine Disease
February 01, 2022
GENEVA, SWITZERLAND / ACCESSWIRE / February 1, 2022 / RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF)(OTCQB:RLFTY) ("Relief"), a biopharmaceutical company seeking to provide patients therapeutic...
From
Relief Therapeutics Holdings AG
Via
AccessWire
Topics
Intellectual Property
Exposures
Intellectual Property
Relief Therapeutics Announces Results of Extraordinary General Meeting of RELIEF THERAPEUTICS Holding SA
January 31, 2022
GENEVA, SWITZERLAND / ACCESSWIRE / January 31, 2022 / RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF)(OTCQB:RLFTY) (" Relief "), a biopharmaceutical company seeking to provide patients...
From
Relief Therapeutics Holdings AG
Via
AccessWire
Relief Reports that its U.S. Collaboration Partner has Announced Receipt of Initial Report of Patient Safety and Survival from Right to Try Use of Aviptadil During Omicron Surge
January 27, 2022
GENEVA, SWITZERLAND / ACCESSWIRE / January 27, 2022 / RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF)(OTCQB:RLFTY) ("Relief"), a biopharmaceutical company seeking to provide patients therapeutic...
From
Relief Therapeutics Holdings AG
Via
AccessWire
Topics
Death
Exposures
COVID-19
Death
Relief Therapeutics' Wholly Owned Subsidiary, APR Applied Pharma Research, Receives Notice of Allowance of Key U.S. Patent Application Covering Ready to Use Diclofenac Stick Packs
January 24, 2022
Notice of Allowance of Patent Application for a Non-Steroidal Anti-Inflammatory, Diclofenac Potassium, Strengthens Proprietary Position in U.S. until 2039 GENEVA, SWITZERLAND / ACCESSWIRE / January 24,...
From
Relief Therapeutics Holdings AG
Via
AccessWire
Topics
Intellectual Property
Exposures
Intellectual Property
Relief Reports US Collaboration Partner Announces Expansion of Aviptadil US Expanded Access & Right to Try Programs for Patients w/COVID-19 Respiratory Failure who've Exhausted All Approved Therapies
January 19, 2022
GENEVA, SWITZERLAND / ACCESSWIRE / January 19, 2022 / RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF)(OTCQB:RLFTY) ("Relief"), a biopharmaceutical company seeking to provide patients therapeutic...
From
Relief Therapeutics Holdings AG
Via
AccessWire
Exposures
COVID-19
Relief Therapeutics Comments on NRx Pharmaceuticals' Press Release Reporting on its Recently Filed Lawsuit
January 14, 2022
GENEVA, SWITZERLAND / ACCESSWIRE / January 14, 2022 / RELIEF THERAPEUTICS Holding SA (SIX:RLF, OTCQB:RLFTF, RLFTY) (" Relief "), a biopharmaceutical company seeking to provide patients therapeutic...
From
Relief Therapeutics Holdings AG
Via
AccessWire
Topics
Lawsuit
Exposures
Financial
Legal
The Daily Biotech Pulse: Adagio's Antibody Effective Against Omicron, Sarepta Terminates Gene Therapy Deal, AstraZeneca Inks Oncology Pact
January 13, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Adagio Says Lead Monoclonal Antibody Effective Against Omicron Variant Adagio...
Via
Benzinga
NRx Pharma Files Counterclaim Against Relief Therapeutics Over COVID-19 Candidate Rights
January 13, 2022
NRx Pharmaceuticals Inc (NASDAQ: NRXP) has filed a counterclaim against its former partner, Relief Therapeutics Holdings (OTC: RLFTF), in an ongoing...
Via
Benzinga
Relief Comments on Lawsuit Filed Against It by NeuroRx
January 12, 2022
GENEVA, SWITZERLAND / ACCESSWIRE / January 12, 2022 / RELIEF THERAPEUTICS Holding SA (SIX: RLF)(OTCQB:RLFTF)(OTCQB:RLFTY) (" Relief "), a biopharmaceutical company seeking to provide patients...
From
Relief Therapeutics Holdings AG
Via
AccessWire
Topics
Lawsuit
Exposures
Financial
Legal
Relief Reports US Collab. Partner Announces Submission to FDA seeking EUA for Aviptadil for Pts at Immediate Risk of Death from COVID-19 Despite Treatment w/Remdesivir, Other Approved Therapies
January 06, 2022
GENEVA, SWITZERLAND / ACCESSWIRE / January 6, 2022 / RELIEF THERAPEUTICS Holding SA (SIX:RLF, OTCQB:RLFTF, RLFTY) (" Relief "), a biopharmaceutical company seeking to provide patients therapeutic...
From
Relief Therapeutics Holdings AG
Via
AccessWire
Topics
Lawsuit
Exposures
COVID-19
Financial
Legal
NRXP Stock Alert: The Covid-19 News Lifting NRx Pharmaceuticals Today
January 05, 2022
News of a potential Covid-19 treatment breakthrough has NRXP stock rising today. Here's what you need to know about this FDA filing.
Via
InvestorPlace
BYND Stock: 11 Things for Plant-Based Investors to Know About the KFC Beyond Meat ‘Fried Chicken’ News
January 05, 2022
Beyond Meat (BYND) stock is on the move today as investors react to news of Yum Brand's (YUM) KFC adopting plant-based fried chicken.
Via
InvestorPlace
RLFTF Stock Alert: What Is Going on With Relief Therapeutics Today?
January 05, 2022
RLFTF stock and NRXP stock are both gaining this morning after NRx Pharmaceuticals filed for emergency use for its Covid-19 treatment.
Via
InvestorPlace
Relief Therapeutics to Participate in Virtual Investor Conferences in January
January 05, 2022
GENEVA, SWITZERLAND / ACCESSWIRE / January 5, 2022 / RELIEF THERAPEUTICS Holding SA (SIX:RLF, OTCQB:RLFTF, RLFTY) (" Relief "), a biopharmaceutical company seeking to provide patients therapeutic...
From
Relief Therapeutics Holdings AG
Via
AccessWire
Relief Reports that its U.S. Collaboration Partner has Announced the Filing of a Provisional Patent Application for Stable Compositions of Aviptadil Suitable for Human Use
January 04, 2022
GENEVA, SWITZERLAND / ACCESSWIRE / January 4, 2022 / RELIEF THERAPEUTICS Holding SA (SIX:RLF, OTCQB:RLFTF, RLFTY) (" Relief "), a biopharmaceutical company seeking to provide patients therapeutic...
From
Relief Therapeutics Holdings AG
Via
AccessWire
Topics
Intellectual Property
Lawsuit
Exposures
COVID-19
Financial
Intellectual Property
Relief Therapeutics Announces Notice of Extraordinary General Meeting of RELIEF THERAPEUTICS Holding SA
January 03, 2022
GENEVA, SWITZERLAND / ACCESSWIRE / January 3, 2022 / RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF)(OTCQB:RLFTY) ("Relief"), a biopharmaceutical company seeking to provide patients therapeutic...
From
Relief Therapeutics Holdings AG
Via
AccessWire
Exposures
COVID-19
Relief Reports U.S. Collab. Partner Announces Filing Breakthrough Therapy Request for Aviptadil in Pts at Immediate Risk of Death from COVID-19 Despite Treatment w/Remdesivir, Other Approved Therapies
December 30, 2021
GENEVA, SWITZERLAND / ACCESSWIRE / December 30, 2021 /RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF)(OTCQB:RLFTY) ("Relief"), a biopharmaceutical company seeking to provide patients therapeutic...
From
Relief Therapeutics Holdings AG
Via
AccessWire
Exposures
COVID-19
Product Safety
Relief Reports Successful Conclusion of Patent Examination Procedure for Patent Application Entitled, 'Vasoactive Intestinal Peptide (VIP) for the Use in the Treatment of Drug-induced Pneumonitis'
December 28, 2021
GENEVA, SWITZERLAND / ACCESSWIRE / December 28, 2021 / RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF)(OTCQB:RLFTY) ("Relief"), a biopharmaceutical company seeking to provide patients therapeutic...
From
Relief Therapeutics Holdings AG
Via
AccessWire
Topics
Intellectual Property
Exposures
Intellectual Property
Relief Therapeutics Files Registration Statement on Form 20-F with the U.S. Securities and Exchange Commission
December 16, 2021
GENEVA, SWITZERLAND / ACCESSWIRE / December 16, 2021 / RELIEF THERAPEUTICS Holding SA (SIX:RLF, OTCQB:RLFTF, RLFTY) (" Relief "), announced today that it has filed a Registration Statement on Form 20-F...
From
Relief Therapeutics Holdings AG
Via
AccessWire
Topics
Regulatory Compliance
Exposures
Legal
Regulatory
Relief Reports that U.S. Collaboration Partner Announces New, Favorable Safety Report for Aviptadil in NIH Sponsored ACTIV-3b Critical Care Study in Patients with Life-Threatening COVID-19
December 15, 2021
GENEVA, SWITZERLAND / ACCESSWIRE / December 15, 2021 / RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF)(OTCQBRLFTY) (" Relief "), a biopharmaceutical company seeking to provide patients...
From
Relief Therapeutics Holdings AG
Via
AccessWire
Epigenetics, Psychedelics and Stem Cell Therapy are Topics of the Life Sciences Virtual Investor Conference Launching This Thursday
December 14, 2021
Photo by Chris Montgomery on Unsplash The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial...
Via
Benzinga
Relief Reports that its U.S. Collaboration Partner has Agreed with Hungarian Health Officials on a Pathway for Aviptadil
December 10, 2021
GENEVA, SWITZERLAND / ACCESSWIRE / December 10, 2021 / RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF)(OTC PINK:RLFTY) ("Relief"), a biopharmaceutical company seeking to provide patients...
From
Relief Therapeutics Holdings AG
Via
AccessWire
Exposures
COVID-19
Relief Therapeutics Announces Executive Changes
November 30, 2021
- Nermeen Varawalla, MD, PhD, MBA appointed Chief Medical Officer, replacing Gilles Della Corte, MD - Jeremy Meinen promoted to Chief Accounting Officer - Marco Marotta promoted to Chief Business...
From
Relief Therapeutics Holdings AG
Via
AccessWire
Exposures
COVID-19
Relief Reports U.S. Collaboration Partner Identifies Significantly Higher Likelihood of Surviving & Recovering from Critical COVID-19 in Aviptadil Treated Patients Previously Administered Remdesivir
November 29, 2021
GENEVA, SWITZERLAND / ACCESSWIRE / November 29, 2021 / RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF)(OTC PINK:RLFTY) ("Relief"), a biopharmaceutical company seeking to provide patients...
From
Relief Therapeutics Holdings AG
Via
AccessWire
Exposures
COVID-19
FDA Denies Breakthrough Tag For NRx Pharma's COVID-19 Candidate
November 24, 2021
Relief Therapeutics Holding SA's (OTC: RLFTF) collaborating partner NRx Pharmaceuticals Inc (NASDAQ: NRXP) has announced that the FDA has denied...
Via
Benzinga
Exposures
COVID-19
Product Safety
Relief Therapeutics and InveniAI Sign a Strategic Collaboration Agreement to Identify New Product Development Opportunities using Artificial Intelligence
November 24, 2021
GENEVA, SWITZERLAND / ACCESSWIRE / November 24, 2021 / RELIEF THERAPEUTICS Holding SA (SIX:RLF, OTCQB:RLFTF, RLFTY) (" Relief "), announced today that it has signed a collaboration agreement (the "...
From
Relief Therapeutics Holdings AG
Via
AccessWire
Topics
Artificial Intelligence
Intellectual Property
Exposures
Artificial Intelligence
COVID-19
Intellectual Property
Relief Reports that its U.S. Collaboration Partner has Announced the U.S. Food and Drug Administration has Denied Breakthrough Designation for Aviptadil
November 24, 2021
GENEVA, SWITZERLAND / ACCESSWIRE / November 24, 2021 / RELIEF THERAPEUTICS Holding SA (SIX: RLF, OTCQB: RLFTF, RLFTY) (" Relief "), a biopharmaceutical company seeking to provide patients therapeutic...
From
Relief Therapeutics Holdings AG
Via
AccessWire
Exposures
COVID-19
Product Safety
Relief Therapeutics Launches Level 1 ADR Program in the United States
November 18, 2021
GENEVA, SWITZERLAND / ACCESSWIRE / November 18, 2021 / RELIEF THERAPEUTICS Holding SA (SIX:RLF, OTCQB:RLFTF) (" Relief "), announced today that its Form F-6 registration statement has become effective,...
From
Relief Therapeutics Holdings AG
Via
AccessWire
Exposures
COVID-19
< Previous
1
2
3
4
5
6
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.